Monthly Investment Planning for Wegovy vs Mounjaro
Understanding Wegovy vs Mounjaro for Weight Loss Cost Differences
When comparing Wegovy vs Mounjaro for weight loss, the monthly cost structure differs significantly between these prescription-only medicines. Wegovy follows a structured 16-week dose escalation from £79.99 monthly, while Mounjaro has its own pricing framework. Both treatments require ongoing monthly investment for sustained weight management benefits. The key difference lies in their mechanisms—Wegovy uses semaglutide (GLP-1 only) while Mounjaro contains tirzepatide (dual GIP and GLP-1 agonist)—which may influence your prescriber's recommendation and your budget planning.
EverydayMeds provides transparent monthly pricing for both options, allowing you to budget effectively for your chosen treatment. Our clinical team (GPhC #9012878) helps patients understand the long-term financial commitment involved in weight management. Whether you choose Wegovy or Mounjaro, both require consistent monthly investment alongside a reduced-calorie diet and increased physical activity. The monthly cost transparency ensures no unexpected price increases during your treatment journey.
Wegovy vs Mounjaro Monthly Pricing Breakdown UK
Wegovy's monthly cost progression follows a clear escalation schedule: £79.99 for weeks 1-4 (0.25mg), £94.99 for weeks 5-8 (0.5mg), £99.99 for weeks 9-12 (1mg), £139.99 for weeks 13-16 (1.7mg), and £209.99 monthly for maintenance (2.4mg). These prices include our FIRST40 discount for new customers and DOSE25 for returning patients, applied automatically at checkout. Mounjaro pricing differs, and direct comparison helps determine the most cost-effective option for your specific situation.
Our bundle options provide convenience rather than savings, such as the Ultimate Stability Trio (three 2.4mg pens) for £649.99, ensuring three months of maintenance supply. The Intro Duo (0.25mg and 0.5mg) costs £169.99, covering your first two months. These bundles reliable supply continuity and reduce ordering frequency. Both Wegovy and Mounjaro are available from EverydayMeds, and your prescriber can help determine which offers better value for your individual circumstances.
Clinical Evidence Behind Wegovy vs Mounjaro for Weight Loss Investment
The STEP clinical trials demonstrated that patients taking Wegovy alongside diet and exercise achieved approximately 15% average weight loss at 68 weeks, compared to 2.4% with placebo (Wilding et al., NEJM, 2021). These results support the monthly investment in Wegovy treatment. Mounjaro's SURMOUNT trials showed different outcomes, but direct comparison isn't appropriate due to varying trial designs and populations.
When considering Wegovy vs Mounjaro for weight loss, the clinical evidence suggests both treatments may provide significant benefits when used as prescribed. The monthly cost should be weighed against potential long-term health improvements and reduced obesity-related healthcare expenses. Your prescriber will assess which treatment offers the best clinical and economic value based on your individual health profile.
How Wegovy Mechanism Justifies Monthly Investment
Wegovy contains semaglutide, a GLP-1 receptor agonist that mimics your body's natural fullness hormone, helping reduce appetite and promote satiety after smaller meals. This mechanism may help reduce food cravings by working on brain appetite centres, supporting sustainable eating habit changes. The once-weekly injection delivers consistent hormone-like effects throughout the week, justifying the monthly investment through continuous appetite regulation. Unlike quick-fix approaches, Wegovy's biological mechanism addresses underlying appetite signals that contribute to weight management challenges. The prescription-only medicine works alongside lifestyle changes, not as a replacement for proper diet and exercise commitment.
Streamlined Wegovy vs Mounjaro Ordering Process
Getting started with either Wegovy or Mounjaro through EverydayMeds involves a simple three-minute online clinical assessment covering your medical history and weight management goals. Our qualified prescribers review your assessment within three working days (or 24 hours with express service), determining which treatment suits your needs and budget. Once approved, we dispatch your medication via next-day delivery using temperature-controlled cold-chain logistics to preserve medication integrity. The straightforward process eliminates lengthy GP waiting times while maintaining full clinical oversight. Both treatments require identical ordering procedures, making cost comparison the primary decision factor.
Practical Storage Considerations Affecting Monthly Costs
Wegovy offers superior storage flexibility compared to Mounjaro, remaining stable at room temperature for six weeks once removed from the fridge, versus Mounjaro's 21-day limit. This storage advantage reduces wastage risk if you travel frequently or forget to refrigerate immediately, protecting your monthly investment. The FlexTouch pen design requires refrigeration at 2-8°C before first use, then allows extended room temperature storage below 30°C. Each pen contains four doses for weekly injections, meaning monthly supply planning involves one pen per month during dose escalation. The storage flexibility particularly benefits those with unpredictable schedules, ensuring your monthly medication investment doesn't suffer from storage mishaps.
Long-term Budget Planning for Wegovy vs Mounjaro Weight Loss
Annual Wegovy costs at maintenance dose (2.4mg) total approximately £2,520 using our DOSE25 returning customer discount, providing clear long-term budget planning. The initial 16-week escalation costs £514.96 total, followed by consistent £209.99 monthly maintenance pricing. This transparent pricing structure allows accurate annual budget allocation for sustained weight management.
When comparing Wegovy vs Mounjaro for weight loss annually, consider that weight management is a long-term commitment—STEP trial extensions showed patients regained approximately two-thirds of lost weight within one year of stopping treatment. The monthly investment should be viewed as ongoing healthcare expenditure rather than temporary cost. Both treatments are available from EverydayMeds with identical service standards, prescription oversight, and delivery reliability.
Maximising Value from Your Wegovy vs Mounjaro Monthly Investment
To optimise your monthly spend on either Wegovy or Mounjaro, ensure you're following the prescribed dosing schedule and lifestyle modifications that enhance treatment effectiveness. Our FIRST40 discount reduces initial costs for new customers, while DOSE25 ensures returning patients maintain affordable ongoing access. Missing doses or inconsistent use reduces the value of your monthly investment, making adherence crucial for cost-effectiveness. Regular monitoring through our clinical team helps identify any issues early, preventing wasted medication or treatment interruptions. Remember to visit https://everydaymeds.co.uk/collections/wegovy to access current pricing and bundle options that suit your budget planning needs.
Reviewed by the EverydayMeds Clinical Team · GPhC #9012878 · Last updated February 2026
